Key clinical point: Balloon pulmonary angioplasty (BPA) was found more effective than riociguat for nonoperable chronic thromboembolic pulmonary hypertension.
Major finding: Relative to riociguat, BPA reduced pulmonary vascular resistance by 40% (P less than .0001) at the end of a 26-week trial.
Data Source: Multicenter, randomized, open-label trial.
Disclosures: Dr. Jaïs reported no potential conflicts of interest.
Jaïs X. ERS 2019.